[1] Kasai T, Suzuki S, Kusano C, et al.High body mass index is correlated with the success of vonoprazan-based second-line therapy for Helicobacter pylori infection[J]. Tohoku J Exp Med, 2021, 253(2): 85-94.
[2] Zhou XZ, Zhu HY, Zhu CP, et al.Helicobacter pylori infection and serum pepsinogen level with the risk of gastric precancerous conditions: a cross-sectional study of high-risk gastric cancer population in China[J]. J Clin Gastroenterl, 2021, 55(9): 778-784.
[3] 杨林,康乐斯基,江华,等.阿坝州藏区人群幽门螺杆菌感染流行病学调查及相关影响因素分析[J].实用医院临床杂志,2019,16(2):18-20.
[4] 杨雪利,何刚,田鹏,等.四川省南充市无症状儿童幽门螺杆菌感染的流行病学调查[J].现代消化及介入诊疗,2020,25(11):1460-1463,1474.
[5] 程贤文,王振东,王峰,等.安康市2009—2019 年幽门螺杆菌感染流行病学调查及与NAFLD发病的相关性[J].中西医结合肝病杂志,2021,31(5):445-448.
[6] Gingold-Belfer R, Niv Y, Schmilovitz-Weiss H, et al.Susceptibility-guided versus empirical treatment for Helicobacter pylori infection: a systematic review and meta-analysis[J]. J Gastroenterl Hepatol, 2021, 36(10): 2649-2658.
[7] 何昀,黄为民,刘志刚,等.佛山地区小学生幽门螺杆菌感染流行病学调查[J].河北医药,2022,44(3):460-463.
[8] 柴蕴珠,王艳红,徐宏蕊.消化内科住院患者幽门螺旋杆菌感染情况[J].华南预防医学,2021,47(1):77-79,83.
[9] 肖一峰,曹微.2100 例中青年人群幽门螺杆菌感染流行病学调查及相关因素研究[J].贵州医药,2021,45(8):1256-1257.
[10] 刘洋,雷琴.重庆市幽门螺杆菌感染儿童社会特征和耐药性分析[J].现代消化及介入诊疗,2020,25(11):1501-1504.
[11] 铁丹丹,赵春燕,范聪聪,等.长春地区幽门螺杆菌耐药性和克拉霉素耐药基因突变位点分析[J].中华微生物学和免疫学杂志,2019,39(4):264-269.
[12] 邬丽娜,张谢,张学松,等.宁波地区不同年龄人群幽门螺杆菌耐药性分析[J].浙江医学,2019,41(8):789-791.